<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39345409</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.09.13.613000</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.09.13.613000</ELocationID><Abstract><AbstractText>In a subset of SARS-CoV-2 infected individuals treated with the oral antiviral nirmatrelvir-ritonavir, the virus rebounds following treatment. The mechanisms driving this rebound are not well understood. We used a mathematical model to describe the longitudinal viral load dynamics of 51 individuals treated with nirmatrelvir-ritonavir, 20 of whom rebounded. Target cell preservation, either by a robust innate immune response or initiation of nirmatrelvir-ritonavir near the time of symptom onset, coupled with incomplete viral clearance, appear to be the main factors leading to viral rebound. Moreover, the occurrence of viral rebound is likely influenced by time of treatment initiation relative to the progression of the infection, with earlier treatments leading to a higher chance of rebound. Finally, our model demonstrates that extending the course of nirmatrelvir-ritonavir treatment, in particular to a 10-day regimen, may greatly diminish the risk for rebound in people with mild-to-moderate COVID-19 and who are at high risk of progression to severe disease. Altogether, our results suggest that in some individuals, a standard 5-day course of nirmatrelvir-ritonavir starting around the time of symptom onset may not completely eliminate the virus. Thus, after treatment ends, the virus can rebound if an effective adaptive immune response has not fully developed. These findings on the role of target cell preservation and incomplete viral clearance also offer a possible explanation for viral rebounds following other antiviral treatments for SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Tin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87544, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Ruy M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87544, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edelstein</LastName><ForeName>Gregory E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boucau</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uddin</LastName><ForeName>Rockib</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>May Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Mamadou</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Manish C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tien</LastName><ForeName>Dessie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Karry</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yijia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagar</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyas</LastName><ForeName>Tammy D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Yumeko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-5556-4618</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammond</LastName><ForeName>Sarah P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyas</LastName><ForeName>Jatin M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-9985-9565</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jonathan Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siedner</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Africa Health Research Institute, KwaZulu-Natal, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barczak</LastName><ForeName>Amy K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0003-3806-2381</Identifier><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemieux</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Havard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perelson</LastName><ForeName>Alan S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-2455-0002</Identifier><AffiliationInfo><Affiliation>Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87544, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Santa Fe Institute, Santa Fe, NM 87501, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI176287</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI110818</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HL143541</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: ASP owns stock in Pfizer. He was also on a Pfizer advisory committee and received an honorarium. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39345409</ArticleId><ArticleId IdType="pmc">PMC11429690</ArticleId><ArticleId IdType="doi">10.1101/2024.09.13.613000</ArticleId><ArticleId IdType="pii">2024.09.13.613000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID 2023.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022;386:1397–408. 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med 2022;387:790–8. 10.1056/NEJMoa2204919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204919</ArticleId><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. The Lancet 2022;400:1213–22. 10.1016/S0140-6736(22)01586-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01586-0</ArticleId><ArticleId IdType="pmc">PMC9539539</ArticleId><ArticleId IdType="pubmed">36216007</ArticleId></ArticleIdList></Reference><Reference><Citation>Charness ME, Gupta K, Stack G, Strymish J, Adams E, Lindy DC, et al. Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment. N Engl J Med 2022;387:1045–7. 10.1056/NEJMc2206449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206449</ArticleId><ArticleId IdType="pmc">PMC9511633</ArticleId><ArticleId IdType="pubmed">36069968</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, et al. SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy: An Observational Study. Ann Intern Med 2023;176:1577–85. 10.7326/M23-1756.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-1756</ArticleId><ArticleId IdType="pmc">PMC10644265</ArticleId><ArticleId IdType="pubmed">37956428</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, et al. Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19). Clin Infect Dis 2023;76:e526–9. 10.1093/cid/ciac512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac512</ArticleId><ArticleId IdType="pmc">PMC9384370</ArticleId><ArticleId IdType="pubmed">35737946</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y, Zhou H, Liu X, Iketani S, Lin M, Zhang X, et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 2023;622:376–82. 10.1038/s41586-023-06609-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06609-0</ArticleId><ArticleId IdType="pubmed">37696289</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Mohri H, Culbertson B, Hong SJ, Duan Y, Luck MI, et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 2023;613:558–64. 10.1038/s41586-022-05514-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05514-2</ArticleId><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura TJ, Choudhary MC, Deo R, Yousuf F, Gomez AN, Edelstein GE, et al. Emerging SARS-CoV-2 Resistance after Antiviral Treatment. JAMA Netw Open 2024;(In Press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11425144</ArticleId><ArticleId IdType="pubmed">39320890</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares H, Baniecki ML, Cardin R, Leister-Tebbe H, Zhu Y, Guan S, et al. Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or Mutations. In Review; 2022. 10.21203/rs.3.rs-1720472/v2.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1720472/v2</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin AF, Clark AE, Chaillon A, Garretson AF, Bray W, Porrachia M, et al. Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment. Clin Infect Dis 2023;76:e530–2. 10.1093/cid/ciac496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac496</ArticleId><ArticleId IdType="pmc">PMC9278181</ArticleId><ArticleId IdType="pubmed">35723411</ArticleId></ArticleIdList></Reference><Reference><Citation>Epling BP, Rocco JM, Boswell KL, Laidlaw E, Galindo F, Kellogg A, et al. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment. Clin Infect Dis 2023;76:573–81. 10.1093/cid/ciac663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac663</ArticleId><ArticleId IdType="pmc">PMC9619622</ArticleId><ArticleId IdType="pubmed">36200701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura TJ. Analysis of emergent SARS-CoV-2 antiviral resistance and its association with virological rebound 2024.</Citation></Reference><Reference><Citation>Zuckerman NS, Bucris E, Keidar-Friedman D, Amsalem M, Brosh-Nissimov T. Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report. Clin Infect Dis 2024;78:352–5. 10.1093/cid/ciad494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad494</ArticleId><ArticleId IdType="pubmed">37596935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y, Kobayashi H, Kakizaki Y, Saito A, Tsutsui T, Kawaguchi M, et al. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. Med 2023;4:813–824.e4. 10.1016/j.medj.2023.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2023.08.001</ArticleId><ArticleId IdType="pubmed">37683636</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AS, Caubel P, Rusnak JM. Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19. N Engl J Med 2022;387:1047–9. 10.1056/NEJMc2205944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2205944</ArticleId><ArticleId IdType="pmc">PMC9513855</ArticleId><ArticleId IdType="pubmed">36069818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath N, O’Horo JC, Challener DW, Tulledge-Scheitel SM, Pike ML, O’Brien M, et al. Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clin Infect Dis 2023;76:e537–9. 10.1093/cid/ciac481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac481</ArticleId><ArticleId IdType="pmc">PMC9384250</ArticleId><ArticleId IdType="pubmed">35698452</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai EY, Lee KA, Nathanson AB, Leonelli AT, Petros BA, Brock-Fisher T, et al. Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir. Infectious Diseases (except HIV/AIDS); 2022. 10.1101/2022.08.04.22278378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.04.22278378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, et al. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis 2023;23:683–95. 10.1016/S1473-3099(22)00873-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00873-8</ArticleId><ArticleId IdType="pmc">PMC9949892</ArticleId><ArticleId IdType="pubmed">36796397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. Infectious Diseases (except HIV/AIDS); 2022. 10.1101/2022.06.21.22276724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276724</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Jeffcoat SE, Biddle JE, Talbot HK, Morrissey KG, Stockwell MS, Maldonado Y, et al. Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals. Clin Infect Dis 2024;78:1175–84. 10.1093/cid/ciad696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad696</ArticleId><ArticleId IdType="pmc">PMC11090981</ArticleId><ArticleId IdType="pubmed">37963102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. eLife 2022;11:e81849. 10.7554/eLife.81849.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.81849</ArticleId><ArticleId IdType="pmc">PMC9711520</ArticleId><ArticleId IdType="pubmed">36383192</ArticleId></ArticleIdList></Reference><Reference><Citation>Deo R, Choudhary MC, Moser C, Ritz J, Daar ES, Wohl DA, et al. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. Ann Intern Med 2023;176:348–54. 10.7326/M22-2381.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-2381</ArticleId><ArticleId IdType="pmc">PMC10052317</ArticleId><ArticleId IdType="pubmed">36802755</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandit JA, Radin JM, Chiang DC, Spencer EG, Pawelek JB, Diwan M, et al. The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls. Clin Infect Dis 2023;77:25–31. 10.1093/cid/ciad102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad102</ArticleId><ArticleId IdType="pmc">PMC10320179</ArticleId><ArticleId IdType="pubmed">36810665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GL- H, Yip TC- F, Lai MS- M, Wong VW- S, Hui DS- C, Lui GC- Y. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. JAMA Netw Open 2022;5:e2245086. 10.1001/jamanetworkopen.2022.45086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.45086</ArticleId><ArticleId IdType="pmc">PMC9856258</ArticleId><ArticleId IdType="pubmed">36472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Perelson AS, Ribeiro RM, Phan T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment. Infectious Diseases (except HIV/AIDS); 2023. 10.1101/2023.05.30.23290747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.05.30.23290747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, et al. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. N Engl J Med 2024;390:230–41. 10.1056/NEJMoa2301425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2301425</ArticleId><ArticleId IdType="pmc">PMC11156186</ArticleId><ArticleId IdType="pubmed">38231624</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X-M, Yang Y, Yao B-F, Ye P-P, Xu Y, Peng S-P, et al. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects. Eur J Pharm Sci 2023;191:106598. 10.1016/j.ejps.2023.106598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2023.106598</ArticleId><ArticleId IdType="pubmed">37783378</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Xu Y, Zheng R, Ye L, Lv G, Cao Z, et al. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial. JAMA Netw Open 2024;7:e241765. 10.1001/jamanetworkopen.2024.1765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.1765</ArticleId><ArticleId IdType="pmc">PMC10938176</ArticleId><ArticleId IdType="pubmed">38477921</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19. N Engl J Med 2023;388:406–17. 10.1056/NEJMoa2208822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208822</ArticleId><ArticleId IdType="pmc">PMC9812289</ArticleId><ArticleId IdType="pubmed">36577095</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan T, Zitzmann C, Chew KW, Smith DM, Daar ES, Wohl DA, et al. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. PLOS Pathog 2024;20:e1011680. 10.1371/journal.ppat.1011680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011680</ArticleId><ArticleId IdType="pmc">PMC11060554</ArticleId><ArticleId IdType="pubmed">38635853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol 2022;7:640–52. 10.1038/s41564-022-01105-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01105-z</ArticleId><ArticleId IdType="pmc">PMC9084242</ArticleId><ArticleId IdType="pubmed">35484231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness. Proc Natl Acad Sci 2021;118:e2111477118. 10.1073/pnas.2111477118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2111477118</ArticleId><ArticleId IdType="pmc">PMC8670484</ArticleId><ArticleId IdType="pubmed">34857628</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens K, Esmaeili S, Schiffer JT. Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses. JCI Insight 2024;9:e176286. 10.1172/jci.insight.176286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.176286</ArticleId><ArticleId IdType="pmc">PMC11141931</ArticleId><ArticleId IdType="pubmed">38573774</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel CE. Antiviral Actions of Interferons. Clin Microbiol Rev 2001;14:778–809. 10.1128/CMR.14.4.778-809.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.14.4.778-809.2001</ArticleId><ArticleId IdType="pmc">PMC89003</ArticleId><ArticleId IdType="pubmed">11585785</ArticleId></ArticleIdList></Reference><Reference><Citation>Talemi SR, Höfer T. Antiviral interferon response at single-cell resolution. Immunol Rev 2018;285:72–80. 10.1111/imr.12699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12699</ArticleId><ArticleId IdType="pubmed">30129203</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt EA, Swick A, Yin J. Rapid induction and persistence of paracrine-induced cellular antiviral states arrest viral infection spread in A549 cells. Virology 2016;496:59–66. 10.1016/j.virol.2016.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.05.019</ArticleId><ArticleId IdType="pmc">PMC5159750</ArticleId><ArticleId IdType="pubmed">27254596</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Sastre A, Biron CA. Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente. Science 2006;312:879–82. 10.1126/science.1125676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1125676</ArticleId><ArticleId IdType="pubmed">16690858</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel CE, Knutson GS. Mechanism of interferon action. Kinetics of decay of the antiviral state and protein phosphorylation in mouse fibroblasts treated with natural and cloned interferons. J Biol Chem 1982;257:11796–801. 10.1016/S0021-9258(18)33834-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)33834-1</ArticleId><ArticleId IdType="pubmed">6181060</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawelek KA, Huynh GT, Quinlivan M, Cullinane A, Rong L, Perelson AS. Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses. PLoS Comput Biol 2012;8:e1002588. 10.1371/journal.pcbi.1002588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002588</ArticleId><ArticleId IdType="pmc">PMC3386161</ArticleId><ArticleId IdType="pubmed">22761567</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer RJ, Oprea M, Antia R, Murali-Krishna K, Ahmed R, Perelson AS. Recruitment Times, Proliferation, and Apoptosis Rates during the CD8 + T-Cell Response to Lymphocytic Choriomeningitis Virus. J Virol 2001;75:10663–9. 10.1128/JVI.75.22.10663-10669.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.22.10663-10669.2001</ArticleId><ArticleId IdType="pmc">PMC114648</ArticleId><ArticleId IdType="pubmed">11602708</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili S, Owens K, Wagoner J, Polyak SJ, White JM, Schiffer JT. A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy. Nat Commun 2024;15:5478. 10.1038/s41467-024-49458-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-49458-9</ArticleId><ArticleId IdType="pmc">PMC11213957</ArticleId><ArticleId IdType="pubmed">38942778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Lau JJ, Au ICH, Lau KTK, Hung IFN, Peiris M, et al. Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation. Nat Commun 2023;14:8377. 10.1038/s41467-023-43706-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43706-0</ArticleId><ArticleId IdType="pmc">PMC10725470</ArticleId><ArticleId IdType="pubmed">38104114</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MS, Brown ER. Rebound of COVID-19 With Nirmatrelvir–Ritonavir Antiviral Therapy. Ann Intern Med 2023;176:1672–3. 10.7326/M23-2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-2887</ArticleId><ArticleId IdType="pmc">PMC10644264</ArticleId><ArticleId IdType="pubmed">37956432</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarelli A, Dobrovolny H. Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action. Interdiscip Sci Comput Life Sci 2024. 10.1007/s12539-024-00643-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12539-024-00643-w</ArticleId><ArticleId IdType="pubmed">39033482</ArticleId></ArticleIdList></Reference><Reference><Citation>Frediani JK, Parsons R, McLendon KB, Westbrook AL, Lam W, Martin G, et al. The New Normal: Delayed Peak Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Loads Relative to Symptom Onset and Implications for Coronavirus Disease 2019 (COVID-19) Testing Programs. Clin Infect Dis 2023:ciad582. 10.1093/cid/ciad582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad582</ArticleId><ArticleId IdType="pmc">PMC10874267</ArticleId><ArticleId IdType="pubmed">37768707</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Guo L, Yuan J, Xu Z, Gu Y, Zhang J, et al. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China. Lancet Microbe 2023;4:e632–41. 10.1016/S2666-5247(23)00139-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00139-8</ArticleId><ArticleId IdType="pubmed">37459867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou K, Hu B, Zhao X, Chi H, Pan J, Zheng Y, et al. Longitudinal observation of viral load in patients infected with Omicron variant and its relationship with clinical symptoms. Front Microbiol 2023;13:1037733. 10.3389/fmicb.2022.1037733.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.1037733</ArticleId><ArticleId IdType="pmc">PMC9880150</ArticleId><ArticleId IdType="pubmed">36713203</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z, Wang L, Bai Y, Liu Y, Lau EH, Galvani AP, et al. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. eLife 2024;13:e89801. 10.7554/eLife.89801.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.89801</ArticleId><ArticleId IdType="pmc">PMC11078542</ArticleId><ArticleId IdType="pubmed">38622989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chen X, Xiao W, Zhao D, Feng L. Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid. J Infect 2022;85:e134–6. 10.1016/j.jinf.2022.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.08.012</ArticleId><ArticleId IdType="pmc">PMC9389848</ArticleId><ArticleId IdType="pubmed">35995309</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Rebound After Paxlovid Treatment 2022.</Citation></Reference><Reference><Citation>Fumagalli V, Di Lucia P, Ravà M, Marotta D, Bono E, Grassi S, et al. Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses. EMBO Mol Med 2023;15:e17580. 10.15252/emmm.202317580.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202317580</ArticleId><ArticleId IdType="pmc">PMC10165354</ArticleId><ArticleId IdType="pubmed">36946379</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin AF, Clark AE, Garretson AF, Bray W, Porrachia M, Santos AT, et al. Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment. Open Forum Infect Dis 2023;10:ofad154. 10.1093/ofid/ofad154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad154</ArticleId><ArticleId IdType="pmc">PMC10122487</ArticleId><ArticleId IdType="pubmed">37096144</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein E. Extended Nirmatrelvir/Ritonavir Treatment Durations for Immunocompromised Patients with COVID-19 (Poster 00658) 2024.</Citation></Reference><Reference><Citation>Nair MS, Luck MI, Huang Y, Sabo Y, Ho DD. Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro. J Infect Dis 2024:jiae385. 10.1093/infdis/jiae385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiae385</ArticleId><ArticleId IdType="pubmed">39132824</ArticleId></ArticleIdList></Reference><Reference><Citation>Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, et al. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. JAMA Netw Open 2024;7:e2354991. 10.1001/jamanetworkopen.2023.54991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.54991</ArticleId><ArticleId IdType="pmc">PMC10858401</ArticleId><ArticleId IdType="pubmed">38335000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Antimicrob Agents Chemother 2022;66:e00632–22. 10.1128/aac.00632-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00632-22</ArticleId><ArticleId IdType="pmc">PMC9578392</ArticleId><ArticleId IdType="pubmed">36094202</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas C, Kamar N, Izopet J. Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment. J Infect 2022;85:e162–3. 10.1016/j.jinf.2022.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.07.014</ArticleId><ArticleId IdType="pmc">PMC9307285</ArticleId><ArticleId IdType="pubmed">35878684</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas C, Trémeaux P, Del Bello A, Latour J, Jeanne N, Ranger N, et al. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab. Clin Microbiol Infect 2022;28:1297–9. 10.1016/j.cmi.2022.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.05.002</ArticleId><ArticleId IdType="pmc">PMC9112603</ArticleId><ArticleId IdType="pubmed">35595125</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen B, Luebke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health - Eur 2021;8:100164. 10.1016/j.lanepe.2021.100164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100164</ArticleId><ArticleId IdType="pmc">PMC8278033</ArticleId><ArticleId IdType="pubmed">34278371</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, et al. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol 2022;7:1906–17. 10.1038/s41564-022-01254-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01254-1</ArticleId><ArticleId IdType="pmc">PMC9675946</ArticleId><ArticleId IdType="pubmed">36289399</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, et al. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses 2021;13:1642. 10.3390/v13081642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081642</ArticleId><ArticleId IdType="pmc">PMC8402761</ArticleId><ArticleId IdType="pubmed">34452507</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberti DC, Kremp MM, Liberti WA, Penkala IJ, Li S, Zhou S, et al. Alveolar epithelial cell fate is maintained in a spatially restricted manner to promote lung regeneration after acute injury. Cell Rep 2021;35:109092. 10.1016/j.celrep.2021.109092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109092</ArticleId><ArticleId IdType="pmc">PMC8220578</ArticleId><ArticleId IdType="pubmed">33979629</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges JP, Vladar EK, Huang H, Mason RJ. Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Thorax 2022;77:203–9. 10.1136/thoraxjnl-2021-217561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-217561</ArticleId><ArticleId IdType="pmc">PMC9273148</ArticleId><ArticleId IdType="pubmed">34404754</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Liu H, Huang H, Li H, Saqi A, Qiang L, et al. Distinct stem/progenitor cells proliferate to regenerate the trachea, intrapulmonary airways and alveoli in COVID-19 patients. Cell Res 2020;30:705–7. 10.1038/s41422-020-0367-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0367-9</ArticleId><ArticleId IdType="pmc">PMC7325636</ArticleId><ArticleId IdType="pubmed">32606347</ArticleId></ArticleIdList></Reference><Reference><Citation>Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med 2022;28:1031–41. 10.1038/s41591-022-01780-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01780-9</ArticleId><ArticleId IdType="pubmed">35361992</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardana M, Webster S, Rivera S, Cortez JM, Breslin J, Pinales C, et al. Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study. Commun Med 2022;2:129. 10.1038/s43856-022-00195-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-022-00195-4</ArticleId><ArticleId IdType="pmc">PMC9553075</ArticleId><ArticleId IdType="pubmed">36238348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitzmann C, Ke R, Ribeiro RM, Perelson AS. How robust are estimates of key parameters in standard viral dynamic models? PLOS Comput Biol 2024;20:e1011437. 10.1371/journal.pcbi.1011437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1011437</ArticleId><ArticleId IdType="pmc">PMC11051641</ArticleId><ArticleId IdType="pubmed">38626190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciupe SM, Tuncer N. Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans. Sci Rep 2022;12:14637. 10.1038/s41598-022-18683-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-18683-x</ArticleId><ArticleId IdType="pmc">PMC9418662</ArticleId><ArticleId IdType="pubmed">36030320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. N Engl J Med 2021;385:2489–91. 10.1056/NEJMc2102507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2102507</ArticleId><ArticleId IdType="pmc">PMC8693673</ArticleId><ArticleId IdType="pubmed">34941024</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol 2022. 10.1038/s41579-022-00822-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00822-w</ArticleId><ArticleId IdType="pmc">PMC9716513</ArticleId><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagstaffe HR, Thwaites RS, Reynaldi A, Sidhu JK, McKendry R, Ascough S, et al. Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults. Sci Immunol 2024;9:eadj9285. 10.1126/sciimmunol.adj9285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.adj9285</ArticleId><ArticleId IdType="pubmed">38335268</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucau J, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, et al. Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection. N Engl J Med 2022;387:275–7. 10.1056/NEJMc2202092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202092</ArticleId><ArticleId IdType="pmc">PMC9258747</ArticleId><ArticleId IdType="pubmed">35767428</ArticleId></ArticleIdList></Reference><Reference><Citation>Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of Influenza A Virus Infection in Humans. J Virol 2006;80:7590–9. 10.1128/JVI.01623-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01623-05</ArticleId><ArticleId IdType="pmc">PMC1563736</ArticleId><ArticleId IdType="pubmed">16840338</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenz RA, Quinlivan M, Elton D, MacRae S, Blunden AS, Mumford JA, et al. Dynamics of Influenza Virus Infection and Pathology. J Virol 2010;84:3974–83. 10.1128/JVI.02078-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02078-09</ArticleId><ArticleId IdType="pmc">PMC2849502</ArticleId><ArticleId IdType="pubmed">20130053</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Lambris JD, Ting JP, Tsang JS. Considering innate immune responses in SARS-CoV-2 infection and COVID-19. Nat Rev Immunol 2022;22:465–70. 10.1038/s41577-022-00744-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00744-x</ArticleId><ArticleId IdType="pmc">PMC9252555</ArticleId><ArticleId IdType="pubmed">35788185</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit NM, Perelson AS. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol 2004;226:95–109. 10.1016/j.jtbi.2003.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2003.09.002</ArticleId><ArticleId IdType="pubmed">14637059</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AP, Moquin DJ, Bernhauerova V, Smith AM. Influenza Virus Infection Model With Density Dependence Supports Biphasic Viral Decay. Front Microbiol 2018;9:1554. 10.3389/fmicb.2018.01554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01554</ArticleId><ArticleId IdType="pmc">PMC6048257</ArticleId><ArticleId IdType="pubmed">30042759</ArticleId></ArticleIdList></Reference><Reference><Citation>PubChem. Nirmatrelvir
n.d.
https://pubchem.ncbi.nlm.nih.gov/compound/155903259 (accessed March 7, 2024).</Citation></Reference><Reference><Citation>Burnham KP, Anderson DR. Practical Use of the Information-Theoretic Approach. Model Sel. Inference, New York, NY: Springer New York; 1998, p. 75–117. 10.1007/978-1-4757-2917-7_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4757-2917-7_3</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>